Stockreport

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

OnKure Therapeutics, Inc. - Class A  (OKUR) 
PDF -- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations -- Next-generation PI3K [Read more]